GLP-1s and Alcohol Cravings: What the Research Actually Found

One of the most consistent things people report on GLP-1 medications has nothing to do with food: they stop wanting to drink. Not a decision, not an effort — the desire quietly isn't there.

That observation has now been tested in a randomised controlled trial, and the results are more interesting and more limited than the headlines suggested. Here's what was actually measured.

The trial

"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial", published in *JAMA Psychiatry* in 2025 (Hendershot and colleagues).

Note the doses. These are starting and early-titration doses, well below the 2.4 mg used for weight management. That matters for interpreting the result — the effect appeared at low exposure.

What changed, and what didn't

This is the part that gets flattened in coverage. The trial found a specific pattern, not a general one.

Semaglutide significantly reduced:

• Drinks per drinking day (β −0.41; 95% CI, −0.73 to −0.09; P = .04)
• Weekly alcohol craving (β −0.39; 95% CI, −0.73 to −0.06; P = .01)

Semaglutide did not significantly reduce:

• Average drinks per calendar day
• The number of drinking days

In a laboratory self-administration task after treatment, participants on semaglutide consumed less alcohol by weight (β −0.48; P = .01) and reached a lower peak breath alcohol concentration (β −0.46; P = .03), with medium-to-large effect sizes.

There was also an unexpected finding: among participants who smoked, semaglutide predicted greater relative reductions in cigarettes per day (β −0.10; P = .005) — consistent with a mechanism acting on reward generally rather than on alcohol specifically.

Read plainly: it didn't stop people drinking. It reduced how much they drank when they did drink, and how much they wanted to. That's a real finding and a narrow one.

Why it might work

The leading hypothesis is that GLP-1 receptor agonists act on brain reward and motivation pathways that aren't food-specific. Preclinical work suggests the effects are centrally mediated and involve changes in reward processing; animal studies have shown semaglutide reducing alcohol intake and relapse-like drinking.

This is the same mechanism people are describing when they say "food noise" went quiet — the sense that a persistent background pull has been turned down. If it applies to appetite for food, there's no strong reason it would stop there. The cigarette finding points the same direction.

The mechanism is still being worked out, and "plausible mechanism plus a small positive trial" is a reason for further research, not a reason to treat the question as settled.

The important limits

Be careful with this evidence, in both directions.

• It's small. 48 participants is a phase 2 signal, not a practice-changing result.
• It's short. Nine weeks says nothing about whether effects persist.
• Participants were not seeking treatment for their drinking, which is a different population from people actively trying to stop.
• Single site.
• Not approved. No GLP-1 is approved by the FDA, MHRA or EMA for alcohol use disorder. Prescribing or seeking one for that purpose is off-label, outside any regulatory review of benefit and risk.

Larger studies are underway and reporting — including a trial of once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity published in The Lancet. The evidence base is moving, which is another reason to treat any single result, including this one, as provisional.

What this means if you've noticed it yourself

If you're on a GLP-1 for weight or diabetes and have found you're drinking less without trying, that's consistent with what the research is finding, and it's a benefit you didn't pay for.

What it isn't:

• A reason to take a GLP-1 for drinking. These medications carry real risks and are approved for specific indications after those risks were weighed against specific benefits. That calculation hasn't been done for alcohol use disorder.
• A treatment for alcohol dependence. Approved treatments exist and work. If drinking is a problem for you, those are the things to ask about.
• Guaranteed to last. Nine weeks of data can't tell you about nine months.

If you're worried about your drinking, please talk to a doctor or an alcohol service. That's not a disclaimer — heavy, dependent drinking can be dangerous to stop abruptly without medical support, and that's exactly the situation where trying to manage it privately with a weight-loss medication is the wrong path.

Drinking on a GLP-1: the practical safety part

Separate from cravings, there's the question of alcohol and these medications together.

There's no absolute prohibition in the labelling, but there are real considerations:

• Alcohol worsens GI side effects. It's one of the most reliable aggravators of nausea and reflux on a GLP-1 — the same list as fatty food and large portions, covered in what makes side effects worse.
• Dehydration. Alcohol is a diuretic, and dehydration is already a live concern on these medications, particularly with GI symptoms. See hydration and GI upset.
• Blood sugar. Alcohol can cause hypoglycaemia, and the risk is meaningfully higher if you also take insulin or a sulfonylurea. If that's you, this is a conversation to have with your prescriber rather than a detail to note.
• Reduced tolerance. Many people report alcohol hitting harder on a GLP-1 — plausible given delayed gastric emptying and smaller food intake. Worth knowing before you drive or make plans.
• Empty calories. Less relevant to safety, relevant to goals.

Worth logging

If your relationship with alcohol has shifted, it's the kind of change that's easy to notice and hard to describe accurately weeks later. A rough note — units, and whether the desire was there — turns "I think I'm drinking less" into something you can actually see, and gives your prescriber a real answer when they ask.

It's also how you'd notice if it drifted back, which is exactly the sort of thing a nine-week trial cannot tell you about.

The wider picture

The alcohol finding sits inside a broader pattern that makes it more credible than an isolated result would be.

The smoking signal. In the same trial, participants who smoked showed greater relative reductions in cigarettes per day. Two different substances, same direction, one mechanism — consistent with an effect on reward processing generally rather than something specific to alcohol.

Animal work came first. Published preclinical studies have shown semaglutide reducing alcohol intake and relapse-like drinking in rodents, with proposed involvement of central GABA neurotransmission. Animal findings frequently fail to replicate in humans, but they establish that a plausible mechanism existed before the human trial, rather than being reverse-engineered from it.

Systematic reviews are appearing. Meta-analyses of GLP-1 receptor agonists and alcohol-related outcomes have begun to be published, which is the normal sign of a field moving from anecdote toward evidence.

And larger trials are reporting. Beyond the JAMA Psychiatry study, a trial of once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity has been published in The Lancet. Anyone reading this months from now should assume the evidence has moved again — and check the current literature rather than relying on this page.

What none of that establishes is that these drugs should be prescribed for drinking. Mechanism plus early trials is how a hypothesis becomes worth testing properly. It is not how a treatment becomes approved.

If you want to raise it with your prescriber

Reasonable to discuss, and worth framing usefully:

• Report what you've noticed, concretely. "I've gone from most evenings to twice a week without deciding to" is more useful than "I think it's helping."
• Be honest about your baseline. Prescribers need the real number to judge risk, including whether reducing intake abruptly is safe for you.
• Ask about interactions specific to you — particularly if you take insulin or a sulfonylurea, or have liver concerns.
• Don't ask for a GLP-1 as an alcohol treatment. If drinking is the primary concern, ask about treatments approved for it. There are several, they work, and they've been evaluated for that purpose.

One safety point that isn't optional: if you drink heavily or daily, stopping suddenly can be dangerous — withdrawal from alcohol dependence can be medically serious. If a GLP-1 has substantially reduced your intake and you're considering stopping altogether, that's a conversation to have with a doctor first, not a change to make alone.

Where to get help

If this article prompted a question about your own drinking, that question is worth following up regardless of what any medication is doing:

• Your GP or primary care doctor — the usual starting point, and they can assess withdrawal risk.
• In the UK: the NHS provides information on alcohol support services, and local alcohol services accept self-referral.
• In the US: SAMHSA's National Helpline provides free, confidential, 24/7 referral and information.
• Peer support — organisations such as AA, SMART Recovery and others, which suit different people differently.

Effective treatment exists and reaching for it early is easier than reaching for it late.

Frequently asked questions

Does semaglutide reduce alcohol cravings? In a 2025 JAMA Psychiatry phase 2 RCT, low-dose semaglutide significantly reduced weekly craving and drinks per drinking day versus placebo. It did not reduce the number of drinking days.

Is it approved for alcohol use disorder? No — not by the FDA, MHRA or EMA. The research is early.

How large was the trial? Small: 48 participants randomised, 9 weeks, one US centre, at doses below those used for weight management.

Can you drink alcohol on a GLP-1? No absolute prohibition, but alcohol worsens GI side effects, contributes to dehydration and affects blood sugar — with higher hypoglycaemia risk on insulin or a sulfonylurea. Ask your prescriber.

Why does alcohol feel less appealing? Most people describe reduced interest rather than changed taste. The leading explanation is action on brain reward pathways that aren't food-specific.

What if I'm worried about my drinking? Talk to a doctor or an alcohol support service. Effective approved treatments exist, and stopping heavy drinking abruptly can be dangerous without medical guidance.

Notice the patterns you'd otherwise forget

Track symptoms and doses → · Set a hydration target → · All Tiro GLP-1 tools →

Tiro is a tracker and companion app. It is not a treatment, does not diagnose, and does not replace your prescriber. Trial results as published in JAMA Psychiatry (Hendershot et al., 2025), "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial."